Aarti Drugs Limited
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations.
What Aarti files
- Others64
- Investor Meet39
- Updates15
- Important12
- Board Meeting10
- PPTs6
Aarti Drugs reports strong Q1 FY27 results: Revenue up 19% to ₹703.6 Cr, EBITDA up 30% to ₹96.9 Cr. Adjusted PAT soared 29% (excluding prior year's tax refund). Specialty Chemicals grew 150%. Expansion includes Sayakha ramp-up and OSD capacity doubling at Baddi.
Aarti Drugs announced a key leadership transition. Rashesh C. Gogri becomes Chairman and MD, while Adhish P. Patil is appointed MD, effective Oct 1, 2026. Outgoing Chairman Prakash M. Patil retires. This move aims to strengthen governance and maintain long-term strategic growth.
Aarti Drugs reported FY26 PAT up 16% to Rs 194.9 Cr, with revenue at Rs 2,567.7 Cr (+7%). Q4 saw strong sequential recovery: revenue Rs 721.1 Cr (+20% QoQ), EBITDA Rs 96.6 Cr (+72% QoQ), driven by Sayakha facility scale-up and better product mix. Formulations and Specialty Chemicals showed strong...
Aarti Drugs' board approved audited financial results for the quarter and year ended March 31, 2026. Annual consolidated revenue was ₹2387.03 Cr, with profit at ₹194.94 Cr. Cost and Internal Auditors were re-appointed, and the Risk Management Committee was re-constituted.
Aarti Drugs re-launched "Saksham Niveshak" to help shareholders claim unpaid dividends. Update KYC details to ensure direct credit and prevent transfers to the investor education fund. Important for investors.